Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
Abstract Acquired resistance to osimertinib is inevitable and heterogeneous despite its documented efficacy against EGFR‐mutated non‐small cell lung cancer (NSCLC). Subsequent therapeutic options assume the dominant form of the resistance mechanism; however, the more rare oncogenic driver, NTRK1 fus...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-11-01
|
| Series: | Respirology Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rcr2.1054 |